Mikicort (Budesonide)

Budesonide, the active ingredient in Mikicort, is a corticosteroid presented as an unspecified strength and dosage form for rectal administration. It provides local anti‑inflammatory action for patients with ulcerative colitis, proctitis and other forms of inflammatory bowel disease affecting the rectum.

GNH USA supplies Mikicort as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with capabilities for bulk and individual packaging to meet diverse market requirements. The company adheres to EU quality standards and provides regulatory support for import and distribution.

Mikicort (budesonide) is used in the management of inflammatory bowel conditions that involve the rectum.

- Ulcerative colitis: reduces mucosal inflammation and promotes remission in distal disease. - Proctitis: alleviates symptoms and induces healing of rectal mucosa. - Inflammatory bowel disease (rectal involvement): provides targeted anti‑inflammatory effect to control disease activity.

Rectal budesonide may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Rectal irritation: mild burning or itching at the application site. - Headache: transient headache without other neurological signs. - Nausea: occasional nausea or mild stomach discomfort. - Diarrhea: loose stools or increased bowel movements.

Serious or Rare Side Effects: - Adrenal suppression: reduced cortisol production with prolonged high‑dose use. - Severe infection: increased susceptibility to bacterial, viral or fungal infections. - Allergic reaction: rash, swelling, or anaphylaxis.

Before initiating therapy, clinicians should consider several safety measures.

- Assess adrenal function: monitor cortisol levels during long‑term therapy. - Screen for infection: avoid use in active systemic infections. - Use with caution in diabetes: may affect glucose control. - Discontinue if hypersensitivity: stop treatment at the first sign of allergic reaction. - Pregnancy and lactation: discuss potential risks with a healthcare provider. - Store at room temperature: keep in original container, protect from moisture and light.

Budesonide may interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - CYP3A4 inhibitors: strong inhibitors such as ketoconazole can increase systemic budesonide exposure. - Live vaccines: immunosuppression may reduce vaccine efficacy. - Systemic antifungals: azole agents may raise budesonide levels.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypokalemia risk. - Anticoagulants: possible increased bleeding risk with mucosal irritation. - NSAIDs: additive gastrointestinal irritation may occur.